BioLineRx and Hemispherian start fourth cohort of GLIX1 Phase 1/2a glioma trial

BioLineRx Ltd. and Hemispherian AS announced the initiation of dosing in the fourth cohort of their open‑label Phase 1/2a study of GLIX1 for recurrent or progressive high‑grade glioma. The study has so far reported no significant treatment‑emergent adverse events and will add window‑of‑opportunity cohorts to directly assess brain penetration and pharmacodynamic activity in human tumor tissue. Pre‑clinical data presented at the Society for Neuro‑Oncology meeting showed GLIX1 eradicated tumors in a SNB19 xenograft model, inhibited growth in U87MG and temozolomide‑resistant PDX models, and demonstrated dose‑dependent brain exposure and 5hmC increases.

The companies expect the first read‑out of clinical results in the first half of 2027, which will inform further development and potential regulatory pathways for GLIX1. Investors will watch for safety and early efficacy signals that could affect the valuation of BioLineRx.

  • 1Dosing was initiated in the fourth cohort of the GLIX1 Phase 1/2a study.
  • 2No significant treatment‑emergent adverse events have been observed to date.
  • 3Remaining cohorts will include patients in a window‑of‑opportunity setting to assess brain penetration and biological activity.
  • 4Pre‑clinical data showed tumor eradication and prolonged survival in the SNB19 cell‑derived xenograft model.
  • 5GLIX1 produced dose‑dependent tumor growth inhibition in U87MG and temozolomide‑resistant PDX models.
  • 6GLIX1 was detected in the brain at all tested dose levels with dose‑dependent increases in tumor 5‑hydroxymethylcytosine.

Sources